Study of SyB P-1501 (Fentanyl HCI) for Treatment of Postoperative Pain

PHASE3TerminatedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

November 21, 2016

Primary Completion Date

July 21, 2017

Study Completion Date

July 21, 2017

Conditions
Postoperative Pain
Interventions
DRUG

SyB P-1501

"After extubation and adequate titration by Fentanyl intravenous injection, the investigational product is applied to outer upper arm or chest on patient who confirmed treatment eligibility. Fentanyl 40 μg per dose is delivered over a 10-minute period by pressing the dosing button by the subject as needed. The 10-minute dosing period is a system lock-out time, allowing for a maximum of 6 doses per hour. One system is operable for 24 hours or until 80 doses are delivered, whichever occurs first.~Duration of application of the investigational product is 24 hours. Duration of application may be extended for up to 72 hours or until the third system is used, whichever occurs first, if the patient requests it and the specified tests can be performed"

DRUG

SyB P-1501 placebo

Identical to SyB P-1501 containing hydrogel that contains the active ingredient fentanyl HCI in its structure and appearance but production of an electric current and subsequent drug administration by iontophoresis are prevented because of its modified circuit.

Trial Locations (29)

Unknown

Research Site, Nagakute

Research Site, Nagoya

Research Site, Toyoake

Research Site, Kobe

Research Site, Kahoku

Research Site, Kanazawa

Research Site, Hiragi

Research Site, Nankoku

Research Site, Sendai

Research Site, Matsumoto

Research Site, Kashihara

Research Site, Kurashiki

Research Site, Sayama

Research Site, Suita

Research Site, Takatsuki

Research Site, Izumo

Research Site, Arakawa City

Research Site, Minato

Research Site, Yonago

Research Site, Ube

Research Site, Chūō

Research Site, Fukuoka

Research Site, Fukushima

Research Site, Kagoshima

Research Site, Kyoto

Research Site, Okayama

Research Site, Saga

Research Site, Tokushima

Research Site, Wakayama

Sponsors
All Listed Sponsors
lead

SymBio Pharmaceuticals

INDUSTRY